Results 71 to 80 of about 11,948 (164)

Unravelling the Major Cardiovascular Risks of Systemic Psoriasis Medications: A Literature Systematic Review

JEADV Clinical Practice, Volume 5, Issue 1, Page 32-58, March 2026.
ABSTRACT Background Psoriasis is a chronic inflammatory dermatological condition associated with an elevated risk of cardiovascular events (CVEs). Systemic therapies have transformed disease management, but their cardiovascular (CV) safety profiles remain incompletely understood and inconsistently reported.
Mai Thi Hoai Son, Yves Julien Mbama Biloa, Pauline Gouttefarde, Thomas Franck, Gilles Cizeron, Mathieu Oriol, François Maccari, Elisa Cinotti, Beatrice Trombert‐Paviot, Bienvenu Bongue, Jean‐Luc Perrot   +10 more
wiley   +1 more source

Predictive Factors of Response and Real‐World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort

International Journal of Dermatology, EarlyView.
Alonso García‐Núñez, Antonio Alcalá Ramírez Del Puerto, Roberto Daza‐García, María Teresa Monserrat‐García, Mercedes Morillo‐Andújar, Javier Jesús Domínguez‐Cruz, Román Barabash‐Neila   +6 more
wiley   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

JEADV Clinical Practice, Volume 5, Issue 1, Page 67-74, March 2026.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo, Antonio Torrelo, Eric L. Simpson, Marjolein De Bruin‐Weller, Diamant Thaçi, Norito Katoh, Silvia Sabatino, Andrew Buchanan, Kasia Morawska, Samuel Ogwu, Karen Denning, Jonathan I. Silverberg   +11 more
wiley   +1 more source

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, Volume 5, Issue 1, Page 101-116, March 2026.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source

Therapeutic Response of Alopecia Areata-Associated Nail Changes to Baricitinib

Case Reports in Dermatological Medicine
Nail changes are seen in some individuals with alopecia areata, with the most common variants including pitting and trachyonychia. The nail findings are presumed to be due to the same lymphocytic infiltration seen in hair bulbs in individuals with AA ...
Ashley Wittmer, Katherine De Jong, Lauren Bolish, Lindsey Finklea   +3 more
doaj   +1 more source

Successful Treatment of Paediatric Necrobiosis Lipoidica With Baricitinib

JEADV Clinical Practice, Volume 5, Issue 1, Page 246-249, March 2026.
ABSTRACT Necrobiosis lipoidica (NL) is a rare, chronic granulomatous condition that typically presents as sharply demarcated plaques with telangiectasia and atrophic centres. Paediatric cases are uncommon, and treatment options often fail to address refractory cases.
P. Simões Farinha, M. J. Paiva‐Lopes
wiley   +1 more source

Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis, Treatment, and Prevention

MedComm, Volume 7, Issue 3, March 2026.
This review focuses on the clinical features, molecular mechanisms, treatment methods, and preventive measures of the VZV, with the aim of providing a theoretical basis for the development of new treatment and prevention methods for HZ. ABSTRACT Varicella zoster virus (VZV) is a ubiquitous human herpesvirus that establishes lifelong latency and causes ...
Lei Peng, Honghao Song, Tianying Li, Yuqing Ma, Chen Yan, Yuhan Cao, Kaiqiang Sun, Chaofeng Han, Hongbin Yuan   +8 more
wiley   +1 more source

No Increased Risk of Thromboembolic Events During 6‐Month Treatment With Baricitinib in Patients With Alopecia Areata

International Journal of Dermatology, Volume 65, Issue 4, Page 828-830, April 2026.
Giacomo Caldarola, Antonietta Ferretti, Lorenzo Maria Pinto, Leonardo Di Gennaro, Eleonora De Luca, Gennaro Marco Falco, Clara De Simone, Raimondo De Cristofaro, Ketty Peris   +8 more
wiley   +1 more source

Remodeling the Inflammatory Microenvironment: Nanomaterial‐Based Targeted Strategies for Systemic Lupus Erythematosus and Lupus Nephritis

Small Science, Volume 6, Issue 3, March 2026.
Current treatments for severe lupus nephritis are limited by side effects due to poor drug targeting. This review explores how smart nanomaterials—like liposomes and biomimetic carriers—can precisely deliver drugs to overactive immune cells and the kidneys. These nanotherapeutics enhance efficacy, reduce toxicity, and enable combination strategies. The
Cheng Zhou, Jiayi Li, Jian Zhang, Haifeng Wang, Haitao Lu, Shunlai Shang, Wenge Li   +6 more
wiley   +1 more source

Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study

The Journal of Dermatology, Volume 53, Issue 3, Page 454-460, March 2026.
ABSTRACT Tralokinumab, an anti‐IL‐13 antibody, is effective for atopic dermatitis (AD); however, its long‐term (> 1 year) effectiveness specific to each anatomical site is unknown in real‐world settings. To evaluate 72‐week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate‐to‐severe AD treated with
Mizuki Shiba, Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei‐ichiro Motegi, Naoko Kanda   +6 more
wiley   +1 more source